The most important upcoming catalyst in neuroscience is Eli Lilly's TRAILBLAZER-ALZ 3 study, which aims to prevent Alzheimer's in at-risk patients. A positive result is expected to show a much larger effect size than seen in treating existing disease, potentially creating a massive new market and shifting the entire neurodegenerative paradigm.

For intractable diseases like Parkinson's, the IGI takes an 'end-to-end' approach: building better disease models, discovering root causes, and simultaneously exploring multiple treatment modalities like direct CRISPR edits, cell therapies, and microbiome interventions. This tackles the entire problem, not just one piece.

In its Phase 2 trial, Acadia isn't using biomarkers to discover new insights but to confirm patients have the biological underpinnings of Alzheimer's disease. This marks a significant shift, demonstrating that biomarkers have matured into a standard diagnostic component for ensuring a homogenous and accurately defined patient population in clinical research.

Alzheimer's is a disease of midlife. Pathological changes in the brain start to occur from around age 30, but the first noticeable cognitive symptoms typically don't manifest until one's late 60s or 70s. This highlights a crucial, multi-decade window for prevention and intervention.

Voyager CEO Al Sandrock suggests the 30% average efficacy of new Alzheimer's drugs isn't uniform. Instead, some patients may see a complete halt in progression while others see no benefit. He argues the next critical step is predicting these responders, which will determine whether future therapies like anti-tau agents should be added on or used as a replacement.

After several tau-targeting antibodies failed, including J&J's pazdenimab, confidence in blocking extracellular tau is waning. The field's new hope is Biogen’s Biv80, an antisense drug that prevents tau protein production at the mRNA level, a mechanism that has shown potential to reverse pathology in early data.

After Novo Nordisk's GLP-1 trial in Alzheimer's failed to show clinical benefit despite a 10% biomarker improvement, Coya is pursuing a combination therapy. They theorize that adding low-dose IL-2 can synergistically boost biomarkers to the 25-30% range, a level they believe is necessary to achieve clinically meaningful effects.

The long-term vision for Alt-Pep's diagnostic extends beyond symptomatic patients or those with family histories. The goal is for it to become a routine screening assay, administered annually to the general population to catch the disease at its earliest molecular stages, changing the paradigm from treatment to prevention.

Chronic illnesses like cancer, heart disease, and Alzheimer's typically develop over two decades before symptoms appear. This long "runway" is a massive, underutilized opportunity to identify high-risk individuals and intervene, yet medicine typically focuses on treatment only after a disease is established.